Compare Vital Farms Inc (VITL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vital Farms Inc vs Viatris Inc — how do they compare? Vital Farms Inc trades at $9.37 (market cap $405.27M), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 49.4× Vital Farms Inc's market cap, and Viatris Inc pays a 2.75% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vital Farms Inc for 14 Days and Viatris Inc for 57 Days on average.
| VITL | VTRS | |
|---|---|---|
Market Cap | $405.27M | $20.03B |
Volume | 1,810,837 | 14,109,977 |
Sector | Consumer Staples | Health |
52-Week High | $43.68 | $18.27 |
52-Week Low | $8.28 | $9.74 |
Typical Hold Time | 14 Days | 57 Days |
Enterprise Value | $492.28M | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vital Farms (VITL) trades at $9.36, up 1.3% on the day, amid a challenging period marked by recent earnings misses and a bearish technical signal. The stock shows weak profitability with a net margin of 0.02% in 2026, though valuation ratios like P/E of 11.77 and P/S of 0.55 appear modest. Recent news highlights strategic review speculation and institutional buying interest, providing some positive sentiment against operational headwinds.
The outlook remains cautious due to earnings volatility and cash flow concerns, but analyst consensus is bullish with a $13.11 price target. Key risks include egg pricing pressure and execution challenges, while potential upside hinges on strategic moves and demand recovery for pasture-raised eggs.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
